RADAR-AD aims to find new digital biomarkers for cognition and function in people living with Alzheimer’s disease. Due to the restrictions surrounding the COVID-19 pandemic, enrolment of research participants in the RADAR-AD clinical studies was severely hampered. The need for a project extension was therefore clear to all consortium members, and after making some adjustments in the project timeline as well as in the budgets, a new RADAR-AD end date was agreed upon: the new project end date is 30 June 2023.
This extension will, among other things, allow for more time to achieve RADAR-AD’s goals. These include the enrolment of the envisioned 220 participants in the main RADAR-AD study, the analysis of the collected data and performance of modelling work, the engagement with the European Medicines Agency, and development of a sustainability plan for the envisioned results of the project.
This article was originally posted on: https://www.radar-ad.org/newsroom/one-year-extension-radar-ad